S

Sanofi

Global pharma company; vaccines and R&D

Public Affairs Associate Public Affairs Director

Full-TimeDeadline 12/1/26
No salary listed
Senior, Expert
Bachelor's
Beijing, China
In Person
Growth & MarketingPR & Communications

About the job

Requirements
  • A bachelor's degree or above in Public Policy, Political Science, Public Health, Communications, or a related field is required.
  • A minimum of 8–10 years of relevant experience in public affairs, government relations, or healthcare policy is required; pharmaceutical or biopharmaceutical industry experience is preferred.
  • Deep understanding of China's healthcare system, policy landscape, and regulatory environment is required.
  • A proven track record of building and managing relationships with government officials, industry associations, and patient organizations is required.
  • Strong strategic thinking and the ability to translate policy insights into actionable business recommendations are required.
  • Excellent written and verbal communication skills in Mandarin and English are required.
  • The ability to work effectively in a matrix organization and manage multiple priorities is required.
Responsibilities
  • Monitor, analyze, and interpret Chinese healthcare policy developments, regulatory changes, and government initiatives relevant to Sanofi's portfolio.
  • Build and maintain productive relationships with key government bodies, institutional stakeholders, and industry associations, including NHSA, NMPA, NHC, and NDRC.
  • Represent Sanofi in policy dialogues, public consultations, and industry forums to advocate for evidence-based healthcare policies.
  • Develop and implement country-level public affairs strategies aligned with GenMed China business priorities and global public affairs direction.
  • Contribute to product launch strategies from a public affairs perspective, ensuring policy and access considerations are integrated early.
  • Design and execute public awareness campaigns to enhance Sanofi's visibility and credibility with key stakeholders.
  • Engage with patient organizations, scientific societies, and associated institutions to build coalitions and advance shared healthcare goals.
  • Develop and manage strategic partnerships with external stakeholders to support disease awareness and patient access initiatives.
  • Represent Sanofi's patient-centric values in all external engagements.
  • Anticipate and manage potential public affairs risks and issues that may impact Sanofi's reputation or business operations in China.
  • Assist with crisis communication and response plans in coordination with Communications and Legal teams.
  • Partner closely with Medical, Market Access, Regulatory, Legal, and Commercial teams to integrate public affairs strategies into broader business plans.
  • Provide public affairs intelligence and insights to internal stakeholders to inform decision-making.
  • Collaborate with regional and global public affairs teams to align on priorities and share best practices.
Desired Qualifications
  • Experience in the pharmaceutical or biopharmaceutical industry is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Yahoo Finance
Oct 30th, 2026
Sanofi shares jump 6% as it raises 2026 outlook and signals appetite for bigger deals

Sanofi shares jumped nearly 6% on Friday after the drugmaker raised its 2026 outlook and said it is open to larger deals. The company now expects sales to grow in the low teens this year, with business earnings per share up in the mid-teens at constant exchange rates. Third-quarter sales rose 14.3% to 14.44 billion, and operating income was 5.43 billion. Dupixent remained the main growth driver, with sales up 34.8% to 5.7 billion. New medicines added 1.4 billion. Chief financial officer Francois Roger said Sanofi could consider deals above its typical $2 billion to $5 billion range. The company continues to focus on immunology, rare diseases, and vaccines.

Yahoo Finance
Oct 30th, 2026
Sanofi lifts 2026 guidance as Q3 sales rise 14.3% to $15.6B on Dupixent strength

Sanofi reported third-quarter sales of €14.4 billion, up 14.3% at constant exchange rates, and raised its 2026 outlook. Business operating income rose 19.7%, while business EPS increased 19.6%. The company now expects 2026 sales growth of 13% to 15% and business EPS growth of 15% to 17%. Dupixent sales hit €5.7 billion, with more than 1.5 million patients treated worldwide. Sanofi still targets Dupixent sales of €25 billion by 2030. Sanofi is focusing on immunology, rare diseases, and vaccines. It discontinued two development programmes and expanded its Regeneron alliance to four next-generation antibodies. Planned divestments are expected to cut 2027 sales by about €1.3 billion.

Yahoo Finance
Oct 30th, 2026
Sanofi raises 2026 guidance after Q3 sales rise 14.3% to $15.6B, with Dupixent up 34.8%

Sanofi raised its 2026 guidance after third-quarter sales grew 14.3% at constant exchange rates (CER) to €14,444 million. Business earnings per share (EPS) rose 19.6% at CER to €3.55. The company now expects full-year sales to grow by a low-teens percentage at CER, and business EPS by a mid-teens percentage. Dupixent sales rose 34.8% to €5.7 billion. Sales of newly launched drugs, including ALTUVIIIO, Ayvakit, and Rezurock, climbed 31.4% to €1.4 billion. Vaccines sales fell 6.6% to €3.2 billion. Selling and general expenses fell 0.9% to €2.3 billion. Research and development spending was broadly stable at €1.8 billion. Chief executive officer Belén Garijo said the company's priority is to protect earnings when Dupixent loses exclusivity.

PR Newswire
Oct 29th, 2026
Novavax earns $125M milestone as Sanofi starts Phase 3 flu-COVID vaccine trial

Novavax has earned a $125 million milestone payment after Sanofi dosed the fifth patient in a Phase 3 trial of an influenza-COVID-19 combination vaccine in Europe. The trial tests the safety and immune response of Novavax's COVID-19 vaccine, Nuvaxovid, combined with Sanofi's Efluelda/Fluzone High-Dose flu vaccine in adults aged 60 and older. Novavax could receive a $75 million milestone once manufacturing technology transfer is completed, expected in mid-2027. It is also eligible for $225 million upon a US launch of a combination vaccine, plus royalties on Sanofi sales. "To date, the partnership has generated over $1 billion in revenue for Novavax," said chief executive officer John C. Jacobs.

Yahoo Finance
Oct 29th, 2026
Sanofi brings non-mRNA COVID-19 vaccine Nuvaxovid to 10 provinces and Yukon for 2026-2027

Sanofi Canada said its protein-based, non-mRNA COVID-19 vaccine, Nuvaxovid, will be available in all 10 provinces and the Yukon for the 2026-2027 respiratory season. It will be offered through provincial respiratory programs and most private insurers. The vaccine is already available in British Columbia, Alberta, and Quebec. In Ontario, it should reach healthcare provider offices and public health units from the week of October 26, 2026, with pharmacies to follow. Nuvaxovid is approved for people aged 12 and older. Sanofi says pivotal phase 3 trials showed about 90% efficacy against symptomatic COVID-19. Nearly 77% of Canadian adults skipped a COVID-19 vaccine last season, according to the company. Sanofi hopes more choice will encourage uptake.